CXCL1/GRO alpha Secretion Induced by IL‑17/IL‑17A and Neutralization by Human IL‑17 RA/IL‑17 R Antibody.Recombinant Human IL‑17/IL‑17A induces CXCL1/GRO alpha secretion in the HT‑29 human colon adenocarcinoma cell line in a dose-dependent manner (orange line), as measured by the Human CXCL1/GRO alpha DuoSet (Catalog # DY275). CXCL1/GRO alpha secretion elicited by Recombinant Human IL‑17/IL‑17A (40 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human IL‑17 RA/IL‑17 R Monoclonal Antibody (Catalog # MAB177). The ND50 is typically 0.4-2 μg/mL.
Interleukin 17 (also known as CTLA-8) is a T cell-expressed pleotropic cytokine. IL-17 binds to IL-17 receptor (IL-17 R) which shares no homology with any known family of receptors. While the expression of IL-17 is restricted to activated T cells, the IL-17 R mRNA exhibits a broad tissue distribution, and has been detected in virtually all cells and tissues tested. Human IL-17 R is a 120 kDa, 866 amino acid (aa) type I membrane glycoprotein with a 293 aa extracellular domain, a 21 aa carboxy-proximal transmembrane domain, and a 525 aa cytoplasmic tail. Within the ECD, human IL-17 R shares 72% aa sequence identity with mouse and rat IL‑17 R. The signaling events of IL-17 includes activation of NF-kappa B and JNK, and require TNF receptor-associated factors 6 (TRAF6) in the signaling pathway.
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
12 Citations: Showing 1 - 10
Filter your results:
Expand to show all 12 Citations